SIGA Technologies - Monkeypox likely here to stay
With approximately 64k global cases, monkeypox has become a growing concern and is less transient than initially acknowledged. We expect SIGA Technologies, the leading smallpox therapeutic manufacturer, to remain a beneficiary through the monkeypox epidemic. SIGA’s TPOXX therapy has a strong track record in treating smallpox, which is in the same orthopoxvirus family as monkeypox. The company’s planned submission and approval of post-exposure prophylaxis (PEP) remains a key catalyst and the use of TPOXX supports a refined approach to treating monkeypox. Reflecting what we believe are the most likely assumptions, we arrive at a valuation of $19.80/share, up from $9.17/share.
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
- SIGA Technologies - Monkeypox likely here to stay26 Sep 2022